References
- Ashforth E. I. L., Carlile D. J., Chenery R., Houston J. B. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. Journal of Pharmacology and Experimental Therapeutics 1995; 274: 761–766
- Cooper C. S., Grover P. L., Sims P. The metabolism and activation of benzo(a)pyrene. Progress in Drug Metabolism 1983; 7: 295–396
- Carlile D. J., Zomorodi K., Houston J. B. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes and the intact liver. 1996, (submitted)
- Colthup P. V., Felgate C. C., Palmer J. L., Scully N. L. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. Journal of Pharmaceutical Sciences 1991; 80: 868–871
- Dixon C. M., Colthup P. V., Serabjit-Singh C. J., Kerr B. M., Boehlert C. C., Park G. R., Tarbit M. H. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metabolism and Disposition 1995; 23: 1225–1230
- Fischer V., Vickers A. E. M., Heitz F., Mahadevan S., Baldeck J-P., Minery P., Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metabolism and Disposition 1994; 22: 269–274
- Hayes K. A., Brennan B., Chenery R., Houston J. B. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metabolism and Disposition 1995; 23: 353
- Houston J. B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology 1994; 47: 1469–1479
- Kerr B. M., Boulding-Brown S. Y., Lee C. A., Boehlert C. C., Pritchard J. F., Dixon C. M., Colthup P. V., Bayliss M. K., Tarbit M. H., Serabjit-Singh C. J. Cytochrome P450 metabolism of ondansetron by CYP1A2, CYP1A1 and CYP2D6. ISSX Proceedings, vol. 4. Fifth North American ISSX Meeting, Tuscon, Arizona, October, 17–21. ISSX, Bethesda 1993; 137
- Oxford A. W., Bell J. A., Kilpatric G. J., Ireland S. J., Tyers M. B. Ondansetron and related 5-HT3 antagonists: Recent advances. Progress in Medicinal Chemistry 1992; 29: 239–270
- Pritchard J. F. Ondansetron metabolism and pharmacokinetics. Seminars in Oncology 1992; 19: 9–15
- Saynor D. A., Dixon C. M. The metabolism of ondansetron. European Journal of Cancer and Clinical Oncology 1989; 25: S75–77
- Testa B. The Metabolism of Drugs and Other Xenobiotics: Biochemistry of Redox Reactions. Academic, London 1995; 122–163
- Trager W. F. Mechanisms of oxidative functionalization reactions. Concepts in Drug Metabolism. Part A, P. Jenner, B. Testa. Marcel Decker, New York 1990; 177–209
- Wilkinson G. R. Clearance approaches in pharmacology. Pharmacological Reviews 1987; 39: 1–47
- Worboys P. D., Bradbury A., Houston J. B. Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds. Drug Metabolism and Disposition 1995; 23: 393–397
- Worboys P. D., Bradbury A., Houston J. B. Kinetics of drug metabolism in rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes. Drug Metabolism and Disposition 1995; 24: 676–681
- Zomorodi K., Carlile D. J., Houston J. B. Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica 1995; 25: 907–916